Literature DB >> 1324654

Survival after resection of stage II non-small cell lung cancer.

N Martini1, M E Burt, M S Bains, P M McCormack, V W Rusch, R J Ginsberg.   

Abstract

From 1973 to 1989, 214 patients with stage II non-small cell lung cancer were treated by resection and complete mediastinal lymph node dissection. There were 116 adenocarcinomas and 98 squamous cancers. There were 35 T1 N1 and 179 T2 N1 tumors. Whereas T1 tumors were mainly adenocarcinomas (83%), this difference was not apparent in T2 lesions. Regardless of histology, half of the patients had a single involved N1 lymph node. Lobectomy was performed in 68% of the patients, pneumonectomy in 31%, and wedge resection or segmentectomy in 1%. Lobectomy was sufficient to encompass all disease in 34 of 35 T1 N1 tumors. Only 48 patients (22%) received postoperative external irradiation and 11 patients (5%) received chemotherapy. The overall 5-year disease-free survival was 39%. The best survival rates were in patients who had a single node involved and tumors 3 cm or less in diameter (48%). The pattern of recurrence differed by histology. Local or regional recurrence was more frequent in patients with squamous carcinoma whereas distant metastases were more commonly seen in adenocarcinomas (87%) with brain as the most frequent site (adenocarcinoma, 52%; squamous, 34%). It is concluded that in stage II carcinomas, resection remains the treatment of choice, that mediastinal lymph node dissection provides the most accurate staging, and that the best adjuvant treatment to improve survival is yet to be determined.

Entities:  

Mesh:

Year:  1992        PMID: 1324654     DOI: 10.1016/0003-4975(92)90435-7

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  13 in total

Review 1.  Synthetic Biomaterials from Metabolically Derived Synthons.

Authors:  Nicole G Ricapito; Cynthia Ghobril; Heng Zhang; Mark W Grinstaff; David Putnam
Journal:  Chem Rev       Date:  2016-01-29       Impact factor: 60.622

Review 2.  New prognostic factors in resectable non-small cell lung cancer.

Authors:  E F Smit; H J Groen; T A Splinter; T Ebels; P E Postmus
Journal:  Thorax       Date:  1996-06       Impact factor: 9.139

3.  Prognostic factors in non-small cell lung cancer patients who received neoadjuvant therapy and curative resection.

Authors:  Chen-Ping Hsieh; Ming-Ju Hsieh; Ching-Feng Wu; Jui-Ying Fu; Yun-Hen Liu; Yi-Cheng Wu; Cheng-Ta Yang; Ching-Yang Wu
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

4.  The number of lymph node metastases as a prognostic factor in patients with N1 non-small cell lung cancer.

Authors:  Sirisha Jonnalagadda; Cardinale Smith; Grace Mhango; Juan P Wisnivesky
Journal:  Chest       Date:  2011-02-03       Impact factor: 9.410

5.  Relapse in resected lung cancer revisited: does intensified follow up really matter? A prospective study.

Authors:  Dragan Subotic; Dragan Mandaric; Gordana Radosavljevic; Jelena Stojsic; Milan Gajic; Maja Ercegovac
Journal:  World J Surg Oncol       Date:  2009-11-12       Impact factor: 2.754

6.  Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population.

Authors:  Edmund S Kassis; Ara A Vaporciyan; Stephen G Swisher; Arlene M Correa; B Nebiyou Bekele; Jeremy J Erasmus; Wayne L Hofstetter; Ritsuko Komaki; Reza J Mehran; Cesar A Moran; Katherine M Pisters; David C Rice; Garrett L Walsh; Jack A Roth
Journal:  J Thorac Cardiovasc Surg       Date:  2009-05-28       Impact factor: 5.209

7.  Incidence and patterns of isolated brain failure in stage III non-small-cell lung cancer treated with concurrent chemoradiation therapy.

Authors:  Yasushi Hamamoto; Masaaki Kataoka; Takatoshi Senba; Kotaro Uwatsu; Shogo Oda; Tadaaki Takahashi; Shoji Aono; Shinya Sakai; Takeshi Inoue; Yoshifumi Sugawara
Journal:  Jpn J Radiol       Date:  2009-02-08       Impact factor: 2.374

8.  Concomitant cardiac and pulmonary operations for lung cancer.

Authors:  S La Francesca; O H Frazier; B Radovancĕvić; L F De Caro; G J Reul; D A Cooley
Journal:  Tex Heart Inst J       Date:  1995

9.  Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer.

Authors:  Sonya Haslam; Paul Chrisp
Journal:  Core Evid       Date:  2007-03-31

10.  Risk factors for locoregional recurrence in patients with resected N1 non-small cell lung cancer: a retrospective study to identify patterns of failure and implications for adjuvant radiotherapy.

Authors:  Chengcheng Fan; Shugeng Gao; Zhouguang Hui; Jun Liang; Jima Lv; Xiaozhen Wang; Jie He; Luhua Wang
Journal:  Radiat Oncol       Date:  2013-12-09       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.